DWP Pharma Sdn Bhd Competitors

Growing since 1968, Prime is focused on making a positive difference in the healthcare outcomes for people around the globe. We pride ourselves as a customer-centric company. We truly understand our customer’s needs and work hard to fulfill them at our highest capacity. It has been our benchmark since we started operations in 1968. Prime Pharma has two manufacturing plants and support R&D centers. We are present in over 50+ countries and have successfully registered 400+ dossiers. The company has international offices in Vietnam, Spain, UAE, and Costa Rica. Our manufacturing processes produce a comprehensive, diverse, and highly complementary portfolio of generics and specialty medicines. Further, to provide comprehensive services along with collaborative support in terms of complete product development, dossier preparations, and technology transfer to the global markets, we have ventured into R&D services since 2016. EU-GMP facilities, USFDA facilities, PICS-approved facilities, WHO-GMP facilities Presence in Europe, Latin & Central America, Asia-Pacific, Africa, CIS, and MENA regions.

NOVAPHARMA LTD is a retail company based out of 925 FINCHLEY ROAD, LONDON, United Kingdom.

At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma